Kamada Reports Positive Phase II Data With Inhaled AAT In Cystic Fibrosis

Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow® Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis.

More: continued here

Filed under: Cystic Fibrosis on October 13th, 2008